ZBHZBH
US • —
$86.09
P/E
22.36
PEG
—
FCF Yield
—
Rev Growth YoY
+9.2% YoY
Gross Margin
70.0%
Health Score
6/10
D/E Ratio
0.59
Confidence
LOW
Business Snapshot
This company operates in the medical technology and equipment industry, focusing on musculoskeletal healthcare, surgical solutions, and enabling digital technologies. It competes as a well-established player with a presence across orthopaedics, neurotechnology, and spine surgery, commanding significant market share in joint replacement and trauma. The company falls into the large-cap tier by typical market capitalisation within its peer group. A defining characteristic is its ability to consistently beat earnings expectations, recording positive surprises in each of the last four reported quarters, which suggests reliable management guidance.
Financial Health
Gross margin stands at 70.0%, while the net margin is 9.1%, indicating solid pricing power but relatively modest profit conversion after operating expenses. The debt-to-equity ratio of 0.59x and current ratio of 1.98x point to a healthy balance sheet that is conservatively leveraged and has ample short-term liquidity to cover near-term obligations...
Risk Assessment
- EARNINGS QUALITY — Earnings declined 14.6% year-over-year, indicating deteriorating profitability that contradicts the positive revenue growth trend.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- INSIDER ACTIVITY — Insiders recorded 2 sell transactions versus 0 buys over the last 90 days, suggesting a lack of conviction from company leadership at current prices.
- ANALYST SENTIMENT — Only 35% of analysts rate the stock a Buy, with the majority at Hold (59%), reflecting limited bullish conviction from Wall Street....
Gross margin stands at 70.0%, while the net margin is 9.1%, indicating solid pricing power but relatively modest profit conversion after operating expenses. The debt-to-equity ratio of 0.59x and current ratio of 1.98x point to a healthy balance sheet that is conservatively leveraged and has ample short-term liquidity to cover near-term obligations. Free cash flow data is not available, which limits the ability to assess cash generation quality and reinvestment capacity. Without cash flow visibility, an investor cannot fully gauge the company's ability to fund dividends or share buybacks. Overall financial health appears sound based on margins and leverage, but the absence of cash flow data introduces a meaningful gap in the fundamental picture.
- EARNINGS QUALITY — Earnings declined 14.6% year-over-year, indicating deteriorating profitability that contradicts the positive revenue growth trend. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. - INSIDER ACTIVITY — Insiders recorded 2 sell transactions versus 0 buys over the last 90 days, suggesting a lack of conviction from company leadership at current prices. - ANALYST SENTIMENT — Only 35% of analysts rate the stock a Buy, with the majority at Hold (59%), reflecting limited bullish conviction from Wall Street.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives